Nilaya Varma, Co-founder and CEO, Primus Partners, highlighted the widening gap in proton therapy access between public hospitals offering subsidised care with long waits and private centres charging ₹25–50 lakh per treatment. He emphasized the need for blended financing through CSR support, insurance expansion, and higher healthcare funding, while also noting India’s growing medical tourism appeal driven by lower costs and increasing international patient inflows.